← ANALYST RATINGS · TIPRANKS
vTv Therapeutics (VTVT): analyst forecast and price target
Analyst consensus
Strong Buy5 Buy0 Hold0 Sell
Ratings of 5 analysts in the last 3 months12-month forecast
Based on 5 price targets given in the last 3 months, the average target is $56.80, the highest $67.00, the lowest $42.00. The average is +114.0% from the last price of $26.54.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $30.00 → $28.00−6.7% | Hold | +5.5% | Reiterated | 17.10.26on TipRanks 00:06 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $30.00 → $28.00−6.7% | Hold | +5.5% | Reiterated | 17.10.26on TipRanks 00:06 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $29.00 → $27.00−6.9% | Hold | +1.7% | Reiterated | 17.10.26on TipRanks 00:06 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $27.00 → $25.00−7.4% | Sell | −5.8% | Reiterated | 17.10.26on TipRanks 00:06 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $30.00 → $28.00−6.7% | Hold | +5.5% | Reiterated | 17.10.26on TipRanks 00:06 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $28.00 → $26.00−7.1% | Hold | −2.0% | Reiterated | 17.10.26on TipRanks 00:06 | — | |
| Kambiz Yazdi★★★★★★★★★★#1181 · hits 67% · avg +24.8% | BTIG | $57.00 | Buy | +114.8% | Reiterated | 14.10.26on TipRanks Oct 15 06:10 | −1.4%next day 0.0% | ↗ |
| Adam Walsh★★★★★★★★★★#4262 · hits 43% · avg +4.4% | Roth MKM | $58.00 | Buy | +118.5% | Reiterated | 06.10.26on TipRanks 08:10 | −1.5%next day +3.5% · 5 days −5.9% | ↗ |
| Patrick Dolezal★★★★★★★★★★#1287 · hits 44% · avg +15.1% | LifeSci Capital | $60.00 | Buy | +126.1% | Reiterated | 05.10.26on TipRanks 13:45 | −1.5%next day −1.5% · 5 days 0.0% | ↗ |
| Emily Bodnar★★★★★★★★★★#2140 · hits 39% · avg +7.2% | H.C. Wainwright | $42.00 | Buy | +58.3% | Reiterated | 21.09.26on TipRanks Sep 22 05:35 | −3.1%next day −0.6% · 5 days −1.5% | ↗ |
| Ritu Baral★★★★★★★★★★#49 · hits 58% · avg +46.9% | TD Cowen | $67.00 | Buy | +152.4% | Reiterated | 07.08.26on TipRanks Aug 10 04:00 | +1.6%next day −3.0% · 5 days −15.2% | ↗ |
| Michael King★★★★★★★★★★#11053 · hits 39% · avg −2.3% | Rodman & Renshaw | $67.00 | Buy | +152.4% | Initiated | 30.06.26on TipRanks 08:30 | +3.0%next day −6.8% · 5 days −7.8% | ↗ |
| James Molloy★★★★★★★★★★#12352 · hits 25% · avg −19.8% | Alliance Global Partners | $55.00 | Buy | +107.2% | Reiterated | 14.05.26on TipRanks 07:30 | +20.6%next day −5.9% · 5 days −6.9% | ↗ |
| Michael DiFiore★★★★★★★★★★#10315 · hits 56% · avg −8.0% | Evercore ISI | $44.00 | Buy | +65.8% | Initiated | 12.03.26on TipRanks 06:50 | −2.4%next day −0.7% · 5 days +7.6% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering vTv Therapeutics
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 05.10.26: target $56.80 at a price of $30.57 (+85.8%); now: $56.80 at $26.54 (+114.0%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 4 | 6 | 6 | 6 | 7 |
| Buy | 5 | 3 | 3 | 1 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 05.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-1.09 (from $-1.29 to $-0.67). Last quarter: $-1.05.
Sales
Next quarter’s sales estimate — $0M (from $0M to $0M). Last quarter: $0M.
Best top-analyst consensus in the sector · Healthcare
About vTv Therapeutics
- CEO: Paul J. Sekhri
- Employees: 26
- 3980 Premier Drive, High Point, NC, 27265, US
- www.vtvtherapeutics.com
vTv Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on creating orally administered treatments, with a significant emphasis on diabetes. Its pipeline features lead candidates such as TTP399, an oral, small-molecule, liver-specific glucokinase activator targeting Type 1 diabetes. Another key investigational drug is HPP737, an oral phosphodiesterase type 4 (PDE4) inhibitor that does not cross the blood-brain barrier (non-CNS penetrant), designed to treat inflammatory conditions and psoriasis. Beyond these, vTv Therapeutics' broader clinical portfolio includes: TTP273, an oral small-molecule GLP-1 receptor agonist addressing postprandial glucose excursions in cystic fibrosis-related diabetes. HPP3033, which employs a non-electrophilic strategy to activate the Nrf2 pathway for chronic conditions linked to oxidative stress. Azeliragon, a RAGE antagonist being evaluated for inflammatory lung disorders, notably severe COVID-19, alongside pancreatic and breast cancers. HPP971, an Nrf2 activator aimed at renal diseases, developed in collaboration with pharmaceutical partners. Furthermore, vTv holds a licensing agreement with Reneo Pharmaceuticals, Inc. for the development and commercialization of its peroxisome proliferation-activated receptor delta agonist program, which features the compound HPP593. The company has also established various other licensing and research collaborations with entities such as Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., Newsoara Biopharma Co., Ltd., JDRF International, and Novo Nordisk A/S. Established in 2015, vTv Therapeutics is headquartered in High Point, North Carolina, and operates as a subsidiary of MacAndrews & Forbes Incorporated.
Data from the stock’s TipRanks forecast page, read 96 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗